JP2024519715A5 - - Google Patents

Info

Publication number
JP2024519715A5
JP2024519715A5 JP2023567914A JP2023567914A JP2024519715A5 JP 2024519715 A5 JP2024519715 A5 JP 2024519715A5 JP 2023567914 A JP2023567914 A JP 2023567914A JP 2023567914 A JP2023567914 A JP 2023567914A JP 2024519715 A5 JP2024519715 A5 JP 2024519715A5
Authority
JP
Japan
Prior art keywords
peptide
lipid
lipid composition
composition according
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023567914A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519715A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/027926 external-priority patent/WO2022235972A1/en
Publication of JP2024519715A publication Critical patent/JP2024519715A/ja
Publication of JP2024519715A5 publication Critical patent/JP2024519715A5/ja
Pending legal-status Critical Current

Links

JP2023567914A 2021-05-05 2022-05-05 ペプチド-脂質コンジュゲートを含む脂質組成物 Pending JP2024519715A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184584P 2021-05-05 2021-05-05
US63/184,584 2021-05-05
PCT/US2022/027926 WO2022235972A1 (en) 2021-05-05 2022-05-05 Lipid compositions comprising peptide-lipid conjugates

Publications (2)

Publication Number Publication Date
JP2024519715A JP2024519715A (ja) 2024-05-21
JP2024519715A5 true JP2024519715A5 (cg-RX-API-DMAC10.html) 2025-11-18

Family

ID=83932960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023567914A Pending JP2024519715A (ja) 2021-05-05 2022-05-05 ペプチド-脂質コンジュゲートを含む脂質組成物

Country Status (7)

Country Link
US (1) US20220370624A1 (cg-RX-API-DMAC10.html)
EP (1) EP4334455A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024519715A (cg-RX-API-DMAC10.html)
CN (1) CN118251497A (cg-RX-API-DMAC10.html)
AU (1) AU2022270683A1 (cg-RX-API-DMAC10.html)
CA (1) CA3219053A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022235972A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
CN117098541A (zh) 2020-11-25 2023-11-21 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及相关使用方法
WO2022235923A2 (en) * 2021-05-05 2022-11-10 Arcturus Therapeutics, Inc. Peptide-lipid conjugates
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
CN116396178A (zh) * 2023-01-05 2023-07-07 北京悦康科创医药科技股份有限公司 用于递送核酸的可电离阳离子脂质化合物和组合物及用途
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2024244304A1 (zh) * 2023-06-02 2024-12-05 康希诺生物股份公司 核酸-脂质纳米颗粒组合物、及其冻干制剂、制备方法和应用
WO2025042900A1 (en) * 2023-08-21 2025-02-27 Washington State University Messenger rna treatment for succinic semialdehyde dehydrogenase deficiency
WO2025117732A1 (en) * 2023-11-29 2025-06-05 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
AU2025217182A1 (en) 2024-02-02 2026-08-06 Editas Medicine, Inc. MODIFIED GUIDE RNAs
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
WO2026102260A1 (en) 2024-11-08 2026-05-15 Editas Medicine, Inc. Crispr-related methods and compositions targeting angiopoietin like 3 (angptl3)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
PT2275551E (pt) * 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
US20090220587A1 (en) * 2005-02-01 2009-09-03 United State Army Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands
KR101031049B1 (ko) * 2008-04-17 2011-04-25 한국생명공학연구원 다기능성 퍼플루오르카본 나노 에멀젼을 이용한 세포 표지및 영상화
US8455455B1 (en) * 2010-03-31 2013-06-04 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes involved in hemorrhagic fever
EP3643306A3 (en) * 2011-08-12 2020-08-26 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
US9833518B2 (en) * 2012-04-13 2017-12-05 Case Western Reserve University Heteromultivalent particle compositions
EP2950785A4 (en) * 2013-02-04 2016-09-21 Univ Notre Dame Du Lac NANOPARTICLE-drug delivery systems
CN110003066B (zh) * 2013-11-18 2021-09-03 阿克丘勒斯治疗公司 用于rna递送的可电离的阳离子脂质
HUE052977T2 (hu) * 2014-04-22 2021-06-28 Txp Pharma Gmbh Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok)
WO2016197133A1 (en) * 2015-06-04 2016-12-08 Protiva Biotherapeutics, Inc. Delivering crispr therapeutics with lipid nanoparticles
CN112367974A (zh) * 2018-05-15 2021-02-12 DNALite治疗学公司 粘液穿透肽、递送媒介和治疗方法

Similar Documents

Publication Publication Date Title
US20250145577A1 (en) Stereochemically enriched compositions for delivery of nucleic acids
US11938227B2 (en) Lipid nanoparticles encapsulation of large RNA
US20220370624A1 (en) Lipid compositions comprising peptide-lipid conjugates
US10626393B2 (en) Delivering CRISPR therapeutics with lipid nanoparticles
AU2021325945A1 (en) Method of lyophilizing lipid nanoparticles
US9415109B2 (en) Stable non-aggregating nucleic acid lipid particle formulations
US20210047640A1 (en) Compositions and methods for treating hypertriglyceridemia
WO2016197132A1 (en) Treating hepatitis b virus infection using crispr
JP2019218349A5 (cg-RX-API-DMAC10.html)
Pinheiro et al. Amino acid-based surfactants for biomedical applications
CA2963271A1 (en) Compositions and methods for silencing hepatitis b virus gene expression
WO2017019891A2 (en) Compositions and methods for silencing hepatitis b virus gene expression
JP2011507534A5 (cg-RX-API-DMAC10.html)
WO2015011633A1 (en) Compositions and methods for delivering messenger rna
WO2016183366A2 (en) Compositions and methods for silencing expression of hepatitis d virus rna
US20240300891A1 (en) Ionizable lipids, lipid nanoparticles for mrna delivery and methods of making the same
JP2024513048A5 (cg-RX-API-DMAC10.html)
JP6993359B2 (ja) 生物学的活性物質の細胞への送達のための脂質および複合体
WO2023218420A1 (en) Mrna compositions for inducing latent hiv-1 reversal
WO2025101976A1 (en) Chimeric yeast extracellular vesicles for the enhanced delivery of therapeutic molecules to cells